10-Q: Pasithea Therapeutics Reports Q1 2025 Financial Results and Provides Business Update

Pasithea Therapeutics reports a net loss of $3.56 million for Q1 2025 and provides an update on its clinical development programs and recent financing activities.

Summary

• Pasithea Therapeutics Corp. reported its financial results for the quarter ended March 31, 2025.
• The company is a clinical-stage biotechnology company focused on developing treatments for central nervous system disorders and other diseases.
• The company's lead product candidate is PAS-004, a MEK inhibitor currently in a Phase 1 dose escalation study.
• The company reported a net loss of $3.56 million for the three months ended March 31, 2025, compared to a net loss of $3.86 million for the same period in 2024.
• Research and development expenses were $1.73 million, a slight decrease from $1.75 million in the prior year.
• General and administrative expenses decreased to $1.95 million from $2.29 million in the prior year.
• As of March 31, 2025, the company had cash and cash equivalents of $5.3 million and working capital of $4.5 million.
• The company believes it will need additional funding to meet its needs through the next twelve months.
• Subsequent to the quarter, the company closed a public offering in May 2025, raising gross proceeds of $5.0 million and an additional $1.3 million from warrant exercises.
• The company is advancing PAS-004 into a Phase 1/1b clinical trial in adult patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (NF1-PN).

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company is making progress with its clinical trials and has raised additional capital, it is still operating at a loss and requires additional funding to continue operations.

Positives

• The net loss decreased from $3.86 million in Q1 2024 to $3.56 million in Q1 2025.
• The company successfully completed a public offering in May 2025, raising $5.0 million in gross proceeds and an additional $1.3 million from warrant exercises.
• The company is progressing its lead product candidate, PAS-004, through clinical trials, with a Phase 1/1b trial in adult NF1-PN patients initiated.
• General and administrative expenses decreased by approximately $341,000, or 15%, for the three months ended March 31, 2025 compared to the three months ended March 31, 2024.

Negatives

• The company reported a net loss of $3.56 million for the quarter ended March 31, 2025.
• The company's cash and cash equivalents decreased to $5.3 million as of March 31, 2025, from $6.9 million at the end of 2024.
• The company states that it will not have sufficient working capital to meet its needs through the next twelve months without raising additional capital.

Risks

• The company is dependent on obtaining additional working capital funding from the sale of equity and/or debt securities.
• The company acknowledges that it may not have sufficient working capital to meet its needs through the next twelve months without raising additional capital.
• The company operates in an evolving environment and new risk factors and uncertainties may emerge from time to time.
• The company's future funding requirements will depend on many factors, including the scope, timing, progress and results of discovery, preclinical development, laboratory testing and clinical trials for our product candidates.

Future Outlook

The company expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances its product candidates through all stages of development and clinical trials and seeks regulatory approval. The company expects research and development expenses to increase in fiscal year 2025 as compared to fiscal year 2024 primarily due to (i) an increase in clinical research for PAS-004 related to the ongoing FIH Phase 1 Dose Escalation Study and the planned upcoming phase 1/1b clinical trial of PAS-004 in adult NF1-PN patients, and (ii) an increase in manufacturing costs related to the drug supply for our clinical trials, offset by decreases in pre-clinical research and the reduction in workforce related to the closure of our research laboratory.

Management Comments

• Management believes that the Company will not have sufficient working capital to meet its needs through twelve months from the issuance date of the financial statements included in this Quarterly Report, without raising additional capital.

Industry Context

Pasithea Therapeutics is operating in the competitive biotechnology industry, focusing on treatments for CNS disorders and RASopathies. The company's progress with PAS-004, a MEK inhibitor, places it among other companies developing targeted therapies for MAPK pathway-driven tumors and neurofibromatosis. The successful completion of clinical trials and regulatory approvals are critical for the company to establish a market position.

Comparison to Industry Standards

• Pasithea's focus on CNS disorders and RASopathies aligns with the broader industry trend towards targeted therapies and personalized medicine.
• The company's Phase 1 clinical trial for PAS-004 is comparable to similar early-stage trials conducted by other biotechnology companies developing novel therapeutics.
• The company's cash position of $5.3 million as of March 31, 2025, is relatively low compared to other publicly traded biotechnology companies, highlighting the need for additional funding.
• The company's net loss of $3.56 million for Q1 2025 is within the range of losses reported by other clinical-stage biotechnology companies, but the company's ability to secure additional funding will be critical for its long-term success.

Related Party Transactions

• Prof. Steinman receives $25,000 per quarter for his services under the Steinman Consulting Agreement.

Stakeholder Impact

• Shareholders are impacted by the company's financial performance and ability to raise capital.
• Employees are impacted by the company's ability to fund operations and continue research and development efforts.
• Patients with CNS disorders and RASopathies are impacted by the company's progress in developing new treatments.

Next Steps

• Continue the FIH Phase 1 Dose Escalation Study of PAS-004.
• Advance PAS-004 into a Phase 1/1b clinical trial in adult patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (NF1-PN).
• Seek additional funding through the sale of equity and/or debt securities.
• Continue research and development efforts for PAS-003 and PAS-001.

Key Dates

Keywords

PAS-004, clinical trials, MEK inhibitor, financial results, biotechnology, Pasithea Therapeutics, neurofibromatosis, capital raise, CNS disorders, RASopathies